Home > Insider Trading > Filing (0000899243-20-012071)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1731831	Eidos Therapeutics Inc.	EIDX	Pharmaceutical Preparations (2834)	463733671

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1758363	Cameron Turtle	C/O Eidos Therapeutics, Inc. 101 Montgomery Street, Suite 2000 San Francisco CA 94104	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-05-01	5,000	$13.20	85,155	No	4	M	Direct
Common Stock	Disposition	2020-05-01	7,750	$40.52	77,405	No	4	S	Direct
Common Stock	Disposition	2020-05-01	1,050	$41.23	76,355	No	4	S	Direct
Common Stock	Disposition	2020-05-01	1,180	$42.56	75,175	No	4	S	Direct
Common Stock	Disposition	2020-05-01	20	$43.26	75,155	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-05-01	5,000	$0.00	5,000	$13.20

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
85,000		2028-11-05	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Represents the weighted average sale price of the shares sold from $40.02 to $41.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 through 4.
Represents the weighted average sale price of the shares sold from $41.02 to $41.94 per share.
Represents the weighted average sale price of the shares sold from $42.12 to $43.08 per share.
25% of the shares subject to this option vested and became exercisable on November 5, 2019 and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.